
  
    
      
        Background_NNP
        
          Mitochondrial_NNP genome_NN overview_NN
          The_DT mitochondrial_NN genome_NN itself_PRP encodes_NNS only_RB a_DT handful_NN
          of_IN genes_NNS ._. The_DT largest_JJS mitochondrial_NN genome_NN discovered_VBN to_TO
          date_NN -_: of_IN the_DT protist_NN 
          Reclinomonas_NNP americana_NN -_: codes_NNS for_IN
          97_CD gene_NN products_NNS (_( 67_CD proteins_NNS and_CC 30_CD structural_JJ RNAs_NNP )_) in_IN
          a_DT span_NN of_IN 69_CD ,_, 034_CD base_NN pairs_NNS [_NN 2_CD ]_NN ._. Human_JJ mitochondrial_NN DNA_NNP
          is_VBZ much_RB smaller_JJR ,_, encoding_VBG 37_CD gene_NN products_NNS (_( 13_CD proteins_NNS ,_,
          2_CD rRNAs_NNS and_CC 22_CD tRNAs_NNS )_) over_IN 16_CD ,_, 569_CD base_NN pairs_NNS [_NN 3_CD ]_NN ._. All_DT
          its_PRP$ encoded_JJ proteins_NNS are_VBP directly_RB involved_VBN in_IN oxidative_JJ
          phosphorylation_NN and_CC include_VBP components_NNS of_IN complex_JJ I_PRP (_( NADH_NNP
          dehydrogenase_NN subunits_NNS ND_NNP 1_CD ,_, ND_NNP 2_CD ,_, ND_NNP 3_CD ,_, ND_NNP 4_CD ,_, ND_NNP 4_CD L_NNP ,_, ND_NNP 5_CD ,_,
          ND_NNP 6_CD )_) ,_, complex_JJ III_NNP (_( cytochrome_NN 
          b_SYM )_) ,_, complex_JJ IV_NNP (_( cytochrome_NN oxidase_NN
          subunits_NNS I_PRP ,_, II_NNP and_CC III_NNP )_) and_CC complex_JJ V_NNP (_( mitochondrial_NN
          ATPase_NNP subunits_NNS 6_CD and_CC 8_CD )_) [_NN 4_CD ]_NN ._. All_DT other_JJ human_JJ genes_NNS
          encoding_VBG mitochondrial_NN proteins_NNS (_( total_JJ estimated_VBN at_IN
          around_IN 1_CD ,_, 100_CD [_NN 5_CD ]_NN )_) are_VBP transcribed_JJ in_IN the_DT nucleus_NN ,_,
          translated_VBN in_IN the_DT cytoplasm_NN and_CC their_PRP$ products_NNS imported_VBN
          into_IN mitochondria_NN ._. The_DT interplay_NN between_IN organellar_NN and_CC
          nuclear_JJ genomes_NNS accounts_NNS for_IN a_DT large_JJ part_NN of_IN the_DT
          diversity_NN in_IN mitochondrial_NN pathologies_NNS ._.
          Each_DT human_JJ cell_NN contains_VBZ multiple_JJ mitochondria_NN ,_, often_RB
          dynamically_RB interconnected_VBN in_IN a_DT complex_JJ reticular_NN network_NN
          [_NN 6_CD ,_, 7_CD ]_NN ,_, and_CC each_DT mitochondrion_NN may_MD contain_VB ten_CD or_CC more_JJR
          mitochondrial_NN DNA_NNP (_( mtDNA_NN )_) molecules_NNS ._. Usually_RB all_DT copies_NNS
          of_IN mtDNA_NN are_VBP identical_JJ ,_, a_DT state_NN known_VBN as_IN homoplasmy_NN ._.
          Occasionally_RB ,_, however_RB ,_, mtDNA_NN mutations_NNS occur_VBP and_CC there_EX
          arise_VB two_CD (_( or_CC more_JJR )_) populations_NNS of_IN mtDNA_NN ,_, a_DT state_NN called_VBD
          heteroplasmy_NN [_NN 4_CD ]_NN ._. In_IN fact_NN ,_, heteroplasmic_JJ mtDNA_NN ought_MD to_TO
          be_VB relatively_RB common_JJ ,_, considering_VBG that_IN human_JJ mtDNA_NN
          mutates_NNS 10_CD -_: 20_CD times_NNS faster_RBR than_IN nuclear_JJ DNA_NNP as_IN a_DT result_NN
          of_IN inadequate_JJ proofreading_VBG by_IN mitochondrial_NN DNA_NNP
          polymerases_NNS [_NN 4_CD ]_NN and_CC limited_JJ mtDNA_NN repair_NN capability_NN ._.
          This_DT expectation_NN is_VBZ to_TO some_DT extent_NN borne_VBN out_IN by_IN the_DT
          relative_JJ prominence_NN of_IN mitochondrial_NN disorders_NNS arising_VBG
          from_IN mutations_NNS in_IN the_DT mtDNA_NN -_: although_IN it_PRP is_VBZ also_RB
          important_JJ to_TO note_VB that_IN such_JJ mutations_NNS ,_, being_VBG
          comparatively_RB easy_JJ to_TO identify_VB by_IN sequencing_VBG ,_, will_MD
          naturally_RB have_VB been_VBN among_IN the_DT first_JJ to_TO be_VB
          characterized_VBN ._.
        
        
          Disease_NN classification_NN
          Schapira_NNP has_VBZ devised_VBN a_DT classification_NN scheme_NN for_IN
          mitochondrial_NN defects_NNS [_NN 8_CD ]_NN based_VBN primarily_RB on_IN whether_IN or_CC
          not_RB the_DT affected_VBN gene_NN product_NN is_VBZ directly_RB involved_VBN in_IN
          oxidative_JJ phosphorylation_NN and_CC whether_IN it_PRP is_VBZ encoded_JJ by_IN
          mtDNA_NN or_CC nuclear_JJ DNA_NNP ._.
          A_DT primary_JJ defect_NN in_IN oxidative_JJ phosphorylation_NN defines_VBZ
          class_NN I_PRP ._. Distinct_NNP mitochondrial_NN pathologies_NNS may_MD overlap_VB
          more_JJR than_IN one_CD class_NN ,_, for_IN example_NN Leigh_NNP syndrome_NN (_( see_VB
          below_IN )_) ._. Subclass_NNP Ia_NNP includes_VBZ diseases_NNS arising_VBG from_IN
          mutations_NNS in_IN mtDNA_NN genes_NNS encoding_VBG subunits_NNS of_IN proteins_NNS
          involved_VBN in_IN oxidative_JJ phosphorylation_NN ,_, mitochondrial_NN tRNA_NN
          genes_NNS and_CC mitochondrial_NN rRNA_NN genes_NNS ._. This_DT subclass_NNS has_VBZ
          three_CD related_VBN categories_NNS ,_, depending_VBG on_IN the_DT nature_NN of_IN the_DT
          underlying_VBG mutations_NNS :_: (_( i_NNP )_) large-scale_JJ mtDNA_NN deletions_NNS and_CC
          duplications_NNS ;_: (_( ii_NN )_) point_NN mutations_NNS and_CC small_JJ
          rearrangements_NNS in_IN protein-coding_JJ mtDNA_NN regions_NNS ;_: and_CC (_( iii_NN )_)
          small-scale_JJ mtDNA_NN mutations_NNS in_IN tRNA_NN and_CC rRNA_NN genes_NNS [_NN 8_CD ]_NN ._.
          In_IN order_NN for_IN a_DT class_NN Ia_NNP pathology_NN to_TO present_VB itself_PRP ,_, the_DT
          mtDNA_NN mutation_NN must_MD occur_VB in_IN a_DT significant_JJ fraction_NN of_IN
          the_DT heteroplasmic_JJ mtDNA_NN population_NN ,_, as_RB high_JJ as_IN 60_CD %_NN for_IN
          mtDNA_NN deletions_NNS [_NN 9_CD ]_NN (_( Ia-i_NNP )_) and_CC even_RB up_IN to_TO 95_CD %_NN for_IN tRNA_NN
          mutations_NNS (_( Ia-iii_NNP )_) [_NN 10_CD ]_NN ._. Class_NNP Ib_NNP mitochondrial_NN diseases_NNS
          arise_VBP from_IN mutations_NNS in_IN any_DT of_IN the_DT 70_CD -_: odd_JJ nuclear_JJ genes_NNS
          encoding_VBG protein_NN subunits_NNS involved_VBN in_IN oxidative_JJ
          phosphorylation_NN [_NN 5_CD ]_NN ._. These_DT mutations_NNS can_MD occur_VB in_IN exons_NNS
          or_CC introns_NNS as_RB well_RB as_IN promoters_NNS ._.
          Class_NNP II_NNP mitochondrial_NN disorders_NNS stem_VBP from_IN secondary_JJ
          defects_NNS in_IN oxidative_JJ phosphorylation_NN ._. Class_NNP IIa_NNP genetic_JJ
          pathologies_NNS are_VBP characterized_VBN by_IN mutations_NNS in_IN nuclear_JJ
          mitochondrial_NN protein_NN genes_NNS whose_WP$ products_NNS are_VBP imported_VBN
          into_IN the_DT mitochondria_NN but_CC are_VBP not_RB subunits_NNS of_IN the_DT
          oxidative_JJ phosphorylation_NN apparatus_NN ._. There_EX are_VBP four_CD
          subtypes_NNS :_: (_( i_NNP )_) mtDNA_NN abnormality_NN due_JJ to_TO mutations_NNS in_IN
          nuclear_JJ genes_NNS affecting_VBG mtDNA_NN transcription_NN ,_, translation_NN
          or_CC replication_NN ;_: (_( ii_NN )_) direct_JJ mtDNA_NN damage_NN or_CC defects_NNS in_IN
          mtDNA_NN repair_NN ;_: (_( iii_NN )_) defective_JJ oxidative_JJ phosphorylation_NN
          subunit_NN import_NN ;_: and_CC (_( iv_NN )_) defective_JJ oxidative_JJ
          phosphorylation_NN subunit_NN assembly_NN [_NN 8_CD ]_NN ._. Type_NNP IIb_NNP
          pathologies_NNS arise_VBP from_IN endogenous_JJ and_CC exogenous_JJ
          toxins_NNS ._.
        
      
      
        Results_NNS
        
          Primary_JJ mutational_NN disorders_NNS of_IN oxidative_JJ
          phosphorylation_NN (_( class_NN I_PRP )_)
          
            Leber_NNP 's_POS hereditary_JJ optic_JJ neuropathy_NN
            Leber_NNP 's_POS hereditary_JJ optic_JJ neuropathy_NN (_( LHON_NNP )_) ,_, the_DT most_RBS
            common_JJ cause_NN of_IN male_JJ adolescent_JJ blindness_NN ,_, is_VBZ
            attributed_VBN to_TO mutations_NNS in_IN mtDNA_NN genes_NNS encoding_VBG
            subunits_NNS of_IN complex_JJ I_PRP (_( NADH_NNP dehydrogenase_NN (_( ND_NNP )_) -_:
            alternatively_RB termed_VBD NADH_NNP CoQ_NNP 
            1_CD reductase_NN )_) ._. The_DT most_RBS frequently_RB
            encountered_VBD mutation_NN (_( 50_CD %_NN of_IN cases_NNS among_IN Europeans_NNPS ,_, 95_CD %_NN
            among_IN Asians_NNPS )_) is_VBZ G_NNP 11778_CD A_DT in_IN ND_NNP 4_CD (_( Arg_NNP 340_CD →_NN His_PRP$ )_) ._.
            Additionally_RB ,_, G_NNP 3460_CD A_DT (_( Ala_NNP 52_CD →_NN Thr_NNP )_) in_IN ND_NNP 1_CD ,_, and_CC both_DT
            T_NN 14484_CD C_NNP (_( Met_NNP 64_CD →_NN Val_NNP )_) and_CC G_NNP 14459_CD A_DT (_( Ala_NNP 72_CD →_NN Val_NNP )_) in_IN ND_NNP 6_CD
            rank_NN among_IN the_DT other_JJ primary_JJ LHON-associated_NNP mutations_NNS
            [_NN 4_CD ,_, 11_CD ]_NN ._.
            As_IN seen_VBN in_IN Figure_NN 1_CD ,_, the_DT arginine_NN residue_NN at_IN
            position_NN 340_CD in_IN the_DT human_JJ sequence_NN for_IN ND_NNP 4_CD (_( NU_NNP 4_CD M_NNP __NN HUMAN_NNP )_)
            (_( which_WDT corresponds_NNS to_TO position_VB 300_CD of_IN the_DT profile_NN )_) is_VBZ
            absolutely_RB conserved_JJ across_IN Gram-positive_NNP (_( Rv_NNP 3157_CD )_) ,_,
            Gram-negative_NNP (_( EC_NNP 2277_CD )_) ,_, archaeal_NN (_( PAB_NNP 1432_CD )_) and_CC
            eukaryotic_JJ taxa_NN (_( NU_NNP 4_CD M_NNP __NN HUMAN_NNP and_CC nad_NN 4_CD __NN PRA_NNP )_) ._. The_DT
            pathogenic_JJ mutation_NN of_IN arginine_NN to_TO histidine_NN at_IN this_DT
            position_NN represents_VBZ a_DT moderately_RB significant_JJ divergence_NN
            in_IN sequence_NN ,_, substituting_VBG an_DT imidazole_NN group_NN for_IN a_DT
            guanidino_NN group_NN ._. The_DT two_CD amino-acid_JJ side_NN chains_NNS differ_VBP
            in_IN shape_NN ,_, hydrogen-bonding_JJ capability_NN and_CC degree_NN of_IN
            positive_JJ charge_NN (_( arginine_NN always_RB being_VBG positively_RB
            charged_VBN at_IN physiological_JJ pH_NN ,_, histidine_NN only_RB having_VBG a_DT
            positive_JJ charge_NN about_IN half_PDT the_DT time_NN )_) ._.
            The_DT common_JJ missense_NN substitution_NN in_IN ND_NNP 1_CD that_WDT leads_VBZ
            to_TO LHON_NNP ,_, Ala_NNP 52_CD →_NN Thr_NNP ,_, does_VBZ not_RB have_VB as_IN obvious_JJ an_DT
            explanation_NN for_IN its_PRP$ effect_NN ._. Inspection_NNP of_IN the_DT set_NN of_IN
            aligned_VBN sequences_NNS (_( Figure_NN 2_LS )_) shows_VBZ that_IN this_DT position_NN
            tolerates_NNS glycine_NN and_CC methionine_NN as_RB well_RB as_IN alanine_NN ._.
            Substituting_VBG a_DT threonine_NN for_IN the_DT alanine_NN in_IN the_DT human_JJ
            sequence_NN adds_VBZ a_DT beta-branched_JJ amino_JJ acid_NN capable_JJ of_IN
            disrupting_VBG local_JJ secondary_JJ /_NN tertiary_JJ structure_NN or_CC
            possibly_RB intersubunit_NN interactions_NNS ._. The_DT hydroxyl_NN group_NN
            of_IN the_DT threonine_NN may_MD also_RB form_VB hydrogen_NN bonds_NNS with_IN
            neighboring_VBG amino-acid_JJ residues_NNS so_RB as_IN to_TO add_VB to_TO this_DT
            potential_JJ disruption_NN ._. Further_RB structural_JJ study_NN of_IN
            complex_JJ I_PRP will_MD be_VB required_VBN to_TO explain_VB how_WRB this_DT mutation_NN
            contributes_VBZ to_TO LHON_NNP ._.
            The_DT two_CD common_JJ pathogenic_JJ mutations_NNS in_IN ND_NNP 6_CD (_( Met_NNP 64_CD →_NN
            Val_NNP and_CC Ala_NNP 72_CD →_NN Val_NNP )_) lead_VB to_TO a_DT less_RBR severe_JJ and_CC a_DT very_RB
            severe_JJ form_NN of_IN LHON_NNP ,_, respectively_RB [_NN 12_CD ]_NN ._. As_IN 
            Mycobacterium_NNP
            tuberculosis_NNS already_RB uses_VBZ a_DT valine_NN in_IN position_NN 64_CD
            (_( Figure_NN 3_LS )_) ,_, it_PRP is_VBZ understandable_JJ that_IN the_DT Met_NNP 64_CD →_NN Val_NNP
            substitution_NN should_MD cause_VB a_DT less_RBR severe_JJ disease_NN
            phenotype_NN ._. In_IN position_NN 72_CD ,_, only_RB alanine_NN and_CC methionine_NN
            have_VBP been_VBN seen_VBN among_IN the_DT identified_VBN homologs_NNS ._. As_IN such_JJ ,_,
            the_DT introduction_NN of_IN valine_NN adds_VBZ a_DT β-branched_JJ amino_JJ acid_NN
            at_IN a_DT conserved_JJ non-β-branched_JJ hydrophobic_JJ position_NN ._.
            Additionally_RB ,_, the_DT two_CD eukaryotes_NNS 
            Xenopus_NNP laevis_NNS and_CC 
            Homo_NN sapiens_JJ have_VBP conserved_JJ the_DT
            alanine_NN ,_, whereas_IN the_DT more_RBR distantly_RB related_VBN species_NNS all_DT
            conserve_VB a_DT methionine_NN ._. Whereas_IN only_RB one_CD of_IN the_DT
            NADH-dehydrogenase_NNP subunit_NN mutations_NNS occurs_VBZ at_IN an_DT
            absolutely_RB conserved_JJ position_NN ,_, there_EX are_VBP reasonable_JJ
            explanations_NNS for_IN how_WRB the_DT other_JJ mutations_NNS could_MD manifest_JJ
            their_PRP$ likely_JJ pathology_NN ._.
          
          
            Leigh_NNP syndrome_NN
            Leigh_NNP syndrome_NN (_( also_RB known_VBN as_IN subacute_NN necrotizing_VBG
            encephalomyelopathy_NN )_) is_VBZ another_DT common_JJ mtDNA_NN mutation_NN
            disorder_NN ,_, frequently_RB associated_VBN with_IN cytochrome_NN oxidase_NN
            (_( COX_NNP )_) deficiency_NN [_NN 13_CD ]_NN ,_, though_IN no_DT disease-related_JJ
            mutations_NNS of_IN the_DT mtDNA-encoded_JJ COX_NNP subunits_NNS have_VBP been_VBN
            reported_VBN ._. A_DT single_JJ T-_NNP to-_NN G_NNP transversion_NN at_IN mtDNA_NN
            position_NN 8_CD ,_, 993_CD changes_NNS leucine_NN 156_CD of_IN ATP_NNP synthase_NN
            subunit_NN 6_CD to_TO arginine_NN (_( Leu_NNP 56_CD →_NN Arg_NNP )_) [_NN 14_CD ]_NN (_( Figure_NN
            4_CD a_DT )_) ._.
            Lower_JJR copy_NN numbers_NNS of_IN this_DT mutation_NN (_( ~_NN 70_CD %_NN )_) are_VBP
            associated_VBN with_IN neuropathy_NN ,_, ataxia_NN and_CC retinitis_NNS
            pigmentosa_NN (_( NARP_NNP )_) whereas_IN high_JJ copy_NN numbers_NNS (_( >_NN 90_CD %_NN )_)
            give_VB rise_NN to_TO Leigh_NNP syndrome_NN [_NN 15_CD ]_NN ._. Mutating_NNP the_DT
            conserved_JJ leucine_NN to_TO arginine_NN at_IN position_NN 156_CD is_VBZ a_DT
            drastic_JJ change_NN ,_, disrupting_VBG a_DT γ-branched_JJ aliphatic_JJ
            residue_NN with_IN a_DT basic_JJ guanidino_NN group_NN ,_, a_DT major_JJ chemical_NN
            and_CC presumably_RB structural_JJ substitution_NN ._. In_IN this_DT case_NN
            structural_JJ data_NNS are_VBP available_JJ (_( see_VB Figure_NN 4_CD b_SYM )_) and_CC
            clearly_RB indicates_VBZ the_DT key_JJ location_NN of_IN this_DT residue_NN at_IN
            the_DT protein-protein_JJ interface_NN of_IN two_CD of_IN the_DT subunits_NNS of_IN
            the_DT F_NN 
            0_CD component_NN of_IN complex_JJ V_NNP (_( ATP_NNP
            synthase_NN )_) ._.
            Mutations_NNP found_VBD in_IN at_IN least_JJS two_CD nuclear_JJ genes_NNS also_RB
            correlate_VBP with_IN Leigh_NNP syndrome_NN :_: one_CD for_IN a_DT subunit_NN of_IN the_DT
            pyruvate_NN dehydrogenase_NN complex_JJ and_CC one_CD for_IN surfeit_NN
            locus_JJ protein_NN 1_CD (_( SURF-_NNP 1_LS )_) ,_, which_WDT is_VBZ involved_VBN in_IN the_DT
            assembly_NN of_IN cytochrome_NN 
            c_SYM oxidase_NN ._. As_IN these_DT are_VBP not_RB
            oxidative_JJ phosphorylation_NN proteins_VBZ the_DT mutations_NNS
            qualify_VBP as_IN class_NN II_NNP disorders_NNS ._. A_DT missense_NN mutation_NN
            (_( Arg_NNP 263_CD →_NN Gly_NNP )_) in_IN the_DT E_NNP 1_CD α_NN subunit_NN of_IN pyruvate_NN
            dehydrogenase_NN (_( PDHA_NNP 1_LS )_) has_VBZ been_VBN associated_VBN with_IN Leigh_NNP
            syndrome_NN (_( Figure_NN 5_LS )_) ._. This_DT mutation_NN seems_VBZ to_TO affect_VB
            assembly_NN of_IN the_DT E_NNP 1_CD α-_NN E_NNP 1_CD β_NN heterotetramer_NN [_NN 16_CD ]_NN ._. The_DT
            gene_NN 's_POS location_NN on_IN the_DT X_NNP chromosome_NN complicates_VBZ its_PRP$
            expression_NN pattern_NN in_IN females_NNS as_IN a_DT result_NN of_IN the_DT random_JJ
            pattern_NN of_IN X_NNP inactivation_NN [_NN 17_CD ]_NN ._.
            Whereas_IN only_RB the_DT human_JJ sequence_NN uses_VBZ arginine_NN at_IN
            this_DT position_NN ,_, all_DT other_JJ taxa_NN use_NN a_DT large_JJ hydrophobic_JJ
            amino_JJ acid_NN -_: either_CC tyrosine_NN or_CC leucine_NN ;_: note_NN that_IN even_RB
            an_DT arginine_NN side_NN chain_NN has_VBZ a_DT substantial_JJ hydrophobic_JJ
            segment_NN bearing_VBG its_PRP$ terminal_NN guanidino_NN group_NN ._.
            Substituting_VBG the_DT small_JJ turn-forming_JJ glycine_NN residue_NN
            could_MD have_VB a_DT significant_JJ impact_NN on_IN proper_JJ folding_NN of_IN
            this_DT subunit_NN ._. As_IN shown_VBN in_IN Figure_NN 5_CD b_SYM ,_, Arg_NNP 263_CD is_VBZ located_VBN
            quite_RB close_RB to_TO the_DT active_JJ site_NN of_IN the_DT enzyme_NN ,_, a_DT region_NN
            of_IN the_DT structure_NN where_WRB even_RB small_JJ perturbations_NNS could_MD
            have_VB large_JJ effects_NNS on_IN activity_NN ._.
            The_DT gene_NN for_IN SURF_NNP 1_CD displays_NNS mutations_NNS (_( Gly_NNP 124_CD →_NN Glu_NNP
            and_CC 110246_CD →_NN Thr_NNP )_) that_WDT can_MD also_RB lead_VB to_TO Leigh_NNP syndrome_NN
            [_NN 18_CD ,_, 19_CD ]_NN ._. A_DT number_NN of_IN deletions_NNS seen_VBN in_IN SURF-_NNP 1_CD do_VBP so_RB
            as_RB well_RB ._. The_DT Ile_NNP 124_CD →_NN Glu_NNP substitution_NN disrupts_NNS an_DT
            absolutely_RB conserved_JJ glycine_NN that_IN most_RBS probably_RB
            participates_VBZ in_IN a_DT turn_NN (_( Figure_NN 6_CD )_) ._. The_DT Ile_NNP 246_CD →_NN Thr_NNP
            mutation_NN occurs_VBZ in_IN (_( and_CC probably_RB disrupts_NNS )_) a_DT predicted_VBN
            β_NN sheet_NN believed_VBN to_TO be_VB present_JJ in_IN this_DT protein_NN from_IN all_DT
            higher_JJR eukaryotes_NNS ._. It_PRP occurs_VBZ toward_IN the_DT carboxyl_NN
            terminus_JJ of_IN the_DT human_JJ protein_NN and_CC is_VBZ beyond_IN the_DT region_NN
            covered_VBN by_IN the_DT profile_NN ,_, a_DT reflection_NN of_IN sequence_NN
            divergence_NN between_IN eukaryotes_NNS and_CC prokaryotes_NNS in_IN this_DT
            region_NN ._.
            Mutations_NNP giving_VBG rise_NN to_TO Leigh_NNP syndrome_NN have_VBP also_RB
            been_VBN described_VBN in_IN the_DT flavoprotein_NN subunit_NN (_( Fp_NNP or_CC SDHA_NNP )_)
            of_IN the_DT succinate_NN dehydrogenase_NN complex_JJ (_( SDH_NNP )_) [_NN 20_CD ,_, 21_CD ]_NN ._.
            The_DT mutant_JJ version_NN (_( C_NNP 1684_CD T_NN ,_, Arg_NNP 554_CD →_NN Trp_NNP ;_: Figure_NN 7_CD a_DT )_) of_IN
            SDHA_NNP has_VBZ a_DT normal_JJ K_NNP 
            m_NN and_CC K_NNP 
            i_NNP (_( for_IN malonate_NN )_) but_CC is_VBZ much_RB more_RBR
            sensitive_JJ to_TO downregulation_NN by_IN oxaloacetate_NN (_( OAA_NNP )_) ._.
            Mutating_NNP the_DT conserved_JJ arginine_NN residue_NN at_IN position_NN
            554_CD to_TO a_DT tryptophan_NN causes_VBZ a_DT loss_NN of_IN a_DT polar_JJ residue_NN
            and_CC replacement_NN with_IN a_DT much_RB larger_JJR aromatic_JJ group_NN ._. It_PRP
            is_VBZ not_RB apparent_JJ from_IN the_DT location_NN of_IN this_DT residue_NN in_IN
            the_DT structure_NN (_( Figure_NN 7_CD b_SYM )_) why_WRB this_DT change_NN should_MD have_VB
            such_JJ an_DT effect_NN on_IN function_NN ._. It_PRP lies_VBZ on_IN the_DT surface_NN at_IN a_DT
            considerable_JJ distance_NN from_IN the_DT active_JJ site_NN and_CC does_VBZ not_RB
            have_VB any_DT apparent_JJ role_NN in_IN subunit-subunit_JJ interactions_NNS ._.
            In_IN fact_NN ,_, however_RB ,_, the_DT high_JJ degree_NN of_IN sequence_NN
            conservation_NN over_IN this_DT entire_JJ region_NN (_( Figure_NN 7_CD a_DT )_)
            suggests_VBZ that_IN SDHA_NNP is_VBZ fairly_RB intolerant_NN of_IN mutations_NNS
            here_RB ._. Proper_JJ interaction_NN with_IN the_DT lipid_NN bilayer_NN may_MD
            partly_RB explain_VB the_DT phenomenon_NN ._.
          
        
        
          Secondary_JJ mutational_NN disorders_NNS in_IN oxidative_JJ
          phosphorylation_NN (_( class_NN II_NNP )_)
          
            Mitochondrial_NNP neurogastrointestinal_NN
            encephalomyopathy_NN
            Class_NNP II_NNP mitochondrial_NN disorders_NNS are_VBP due_JJ to_TO
            mutations_NNS in_IN nuclear_JJ mitochondrial_NN protein_NN genes_NNS ._.
            Mitochondrial_NNP neurogastrointestinal_NN encephalomyopathy_NN
            (_( MNGIE_NNP )_) is_VBZ characterized_VBN by_IN ptosis_NNS ,_, progressive_JJ
            external_JJ ophthalmoplegia_NN ,_, gastrointestinal_NN dismotility_NN ,_,
            thin_JJ body_NN habitus_JJ ,_, peripheral_JJ neuropathy_NN ,_, myopathy_NN ,_,
            leukoencephalopathy_NN and_CC lactic_JJ acidosis_NNS and_CC multiple_JJ
            mtDNA_NN deletions_NNS or_CC mtDNA_NN depletion_NN ,_, or_CC both_DT ._. It_PRP is_VBZ a_DT
            class_NN II_NNP Δ-_NN mtDNA_NN depletion_NN disorder_NN ._. It_PRP is_VBZ believed_VBN
            that_IN the_DT pathogenic_JJ mechanism_NN relates_VBZ to_TO aberrant_NN
            thymidine_NN metabolism_NN giving_VBG rise_NN to_TO impaired_VBN mtDNA_NN
            replication_NN and_CC /_NN or_CC mtDNA_NN maintenance_NN [_NN 22_CD ]_NN ._. Missense_NNP
            mutations_NNS in_IN the_DT enzyme_NN thymidine_NN phosphorylase_NN (_( TP_NNP )_)
            (_( Gly_NNP 145_CD →_NN Arg_NNP ,_, Gly_NNP 153_CD →_NN Ser_NNP ,_, Lys_NNP 222_CD →_NN Ser_NNP ,_, Glu_NNP 289_CD →_NN Ala_NNP
            and_CC a_DT few_JJ others_NNS )_) have_VBP been_VBN found_VBN in_IN multiple_JJ MNGIE_NNP
            patients_NNS ,_, and_CC are_VBP believed_VBN to_TO cause_VB the_DT pathology_NN [_NN
            22_CD ]_NN ._.
            TP_NNP catalyzes_NNS a_DT step_NN in_IN the_DT salvage_NN pathway_NN for_IN
            thymine_NN (_( thymidine_NN +_NN phosphate_NN →_NN thymine_NN +_NN
            2_CD -_: deoxy-_NN D-_NNP ribose-_NN 1_CD -_: phosphate_NN )_) ._. In_IN higher_JJR eukaryotes_NNS ,_, TP_NNP
            plays_VBZ the_DT role_NN of_IN platlet-derived_JJ endothelial_NN cell_NN
            growth_NN factor_NN [_NN 23_CD ]_NN ,_, evidently_RB by_IN virtue_NN of_IN the_DT fact_NN
            that_IN the_DT deoxyribose_NN sugar_NN product_NN is_VBZ used_VBN as_IN an_DT
            angiogenesis-inducing_JJ factor_NN [_NN 24_CD ]_NN ._. TP_NNP also_RB has_VBZ
            gliostatin_NN activity_NN ._. Profile-induced_NNP multiple_JJ
            alignments_NNS of_IN this_DT protein_NN show_NN a_DT great_JJ degree_NN of_IN
            conservation_NN over_IN the_DT pathogenic_JJ positions_NNS ,_,
            particularly_RB for_IN the_DT Gly_NNP 153_CD →_NN Ser_NNP mutation_NN (_( Figure_NN 8_CD )_) ._.
            Glycine_NNP is_VBZ absolutely_RB preserved_VBN at_IN this_DT position_NN ,_,
            indicating_VBG that_IN it_PRP may_MD be_VB critical_JJ for_IN proper_JJ folding_NN ._.
            Substituting_VBG a_DT serine_NN could_MD disrupt_VB this_DT ,_, although_IN a_DT
            preceding_VBG glycine_NN may_MD partially_RB compensate_VB ._. The_DT Gly_NNP 145_CD
            →_NN Arg_NNP substitution_NN does_VBZ not_RB disrupt_VB an_DT absolutely_RB
            conserved_JJ position_NN as_IN serine_NN is_VBZ also_RB permitted_VBN ,_, but_CC it_PRP
            introduces_VBZ a_DT large_JJ ,_, basic_JJ (_( and_CC partly_RB hydrophobic_JJ )_)
            residue_NN that_WDT presumably_RB diminishes_VBZ at_IN least_JJS one_CD key_JJ
            function_NN of_IN TP_NNP ._. Lys_NNP 222_CD →_NN Ser_NNP and_CC Glu_NNP 289_CD →_NN Ala_NNP both_DT
            disrupt_VB absolutely_RB conserved_JJ sequence_NN positions_NNS ,_, the_DT
            former_NN of_IN which_WDT lies_VBZ on_IN the_DT periphery_NN of_IN the_DT active_JJ
            site_NN (_( data_NNS not_RB shown_VBN )_) ._. Ghu_NNP 289_CD participates_VBZ in_IN some_DT
            partly_RB buried_VBN conserved_JJ ionic_JJ interactions_NNS more_JJR than_IN 15_CD
            Å_NN distant_JJ from_IN the_DT active_JJ site_NN (_( data_NNS not_RB shown_VBN )_) ._.
          
          
            Deafness-dystonia_NNP
            Deafness-dystonia_NNP ,_, or_CC Mohr-_NNP Tranebjaerg_NNP syndrome_NN ,_, is_VBZ
            a_DT mitochondrial_NN protein_NN import_NN disorder_NN ._. Mutations_NNP in_IN
            DDP_NNP 1_CD (_( deafness_NNS /_NN dystonia_NN peptide_NN 1_LS )_) lead_VB to_TO
            deafness-dystonia_JJ ._. In_IN two_CD cases_NNS seen_VBN to_TO date_NN ,_, a_DT 1_CD bp_NN
            deletion_NN in_IN exon_NN 1_CD (_( T_NN 151_CD del_FW )_) results_NNS in_IN a_DT frameshift_NN ,_,
            leading_VBG to_TO incorporation_NN of_IN 25_CD new_JJ amino_JJ acids_NNS after_IN
            Glu_NNP 38_CD ,_, followed_VBN by_IN a_DT stop_NN codon_NN ._. In_IN a_DT second_JJ case_NN ,_, a_DT 10_CD
            bp_NN deletion_NN in_IN exon_NN 2_CD causes_NNS a_DT frameshift_NN at_IN Met_NNP 48_CD ,_,
            leading_VBG to_TO incorporation_NN of_IN 12_CD new_JJ residues_NNS and_CC a_DT stop_NN
            codon_NN [_NN 25_CD ]_NN ._. These_DT proteins_NNS are_VBP homologous_RB to_TO the_DT yeast_NN
            mitochondrial_NN import_NN protein_NN Tim_NNP 8_CD p_NN (_( YJR_NNP 135_CD W-A_NNP )_) [_NN
            26_CD ]_NN ._.
            As_IN seen_VBN in_IN Figure_NN 9_CD ,_, both_DT frameshift_NN mutations_NNS lead_VBP
            to_TO elimination_NN of_IN a_DT highly_RB conserved_JJ motif_NN (_( NCVpRFaDT_NNP )_)
            near_IN the_DT carboxyl_NN terminus_JJ of_IN the_DT peptide_NN -_: a_DT region_NN
            that_WDT must_MD be_VB critical_JJ to_TO proper_JJ function_NN or_CC folding_VBG ._.
            The_DT recent_JJ publication_NN of_IN the_DT first_JJ DDP_NNP missense_NN
            mutation_NN (_( Cys_NNP 66_CD →_NN Trp_NNP )_) [_NN 27_CD ]_NN strongly_RB supports_VBZ this_DT
            prior_JJ conclusion_NN based_VBN on_IN the_DT frameshifts_NNS ._. As_IN neither_DT
            Tim_NNP 8_CD p_NN nor_CC any_DT close_JJ homolog_NN has_VBZ yet_RB had_VBN its_PRP$ structure_NN
            determined_VBD ,_, we_PRP cannot_NN infer_NN detailed_JJ structure-function_JJ
            relationships_NNS ._. Tim_NNP 8_CD p_NN and_CC Tim_NNP 13_CD p_NN exist_VB in_IN the_DT
            mitochondrial_NN intermembrane_NN space_NN and_CC determine_VB the_DT
            location_NN of_IN Tim_NNP 9_CD p_NN ._. Tim_NNP 9_CD p_NN is_VBZ located_VBN either_CC in_IN the_DT 70_CD
            kDa_NN import_NN complex_JJ between_IN the_DT mitochondrial_NN membranes_NNS
            or_CC the_DT 300_CD kDa_NN TIM_NNP 22_CD complex_JJ embedded_VBN in_IN the_DT inner_JJ
            membrane_NN [_NN 28_CD ]_NN ._. Deletions_NNP of_IN Tim_NNP 8_CD p_NN affect_VBP the_DT ability_NN
            to_TO import_VB mitochondrial_NN proteins_NNS that_WDT become_VBP embedded_VBN
            in_IN the_DT inner_JJ membrane_NN [_NN 29_CD ]_NN ._. It_PRP is_VBZ possible_JJ that_IN the_DT
            frameshift_NN mutations_NNS seen_VBN in_IN deafness-dystonia_JJ
            interfere_VB with_IN the_DT interface_NN between_IN Tim_NNP 8_CD p_NN and_CC
            Tim_NNP 13_CD p_NN ._.
          
          
            Iron-storage_NNP disorders_NNS
            Friedreich_NNP 's_POS ataxia_NN also_RB falls_VBZ into_IN the_DT category_NN of_IN
            a_DT class_NN II_NNP mtDNA_NN damage_NN /_NN repair_NN disorder_NN ._. It_PRP is_VBZ
            characterized_VBN by_IN progressive_JJ gait_NN and_CC limb_NN ataxia_NN ,_, lack_NN
            of_IN tendon_NN reflexes_NNS ,_, dysarthria_NN and_CC pyramidal_NN weakness_NN
            in_IN inferior_JJ limbs_NNS [_NN 30_CD ]_NN ._. Lack_NN of_IN frataxin_NN protein_NN
            causes_VBZ a_DT build-up_NN of_IN iron_NN in_IN the_DT matrix_NN spaces_NNS of_IN the_DT
            mitochondria_NN ._. As_IN iron_NN accumulates_NNS ,_, it_PRP competes_VBZ with_IN
            catalase_NN for_IN hydrogen_NN peroxide_NN and_CC forms_NNS hydroxyl_NN
            radicals_NNS (_( Fe_NNP 2_CD +_NN +_NN H_NNP 
            2_CD O_NNP 
            2_CD →_NN Fe_NNP 3_CD +_NN +_NN OH_NNP -_: +_NN OH_NNP ·_NN )_) -_: so-called_JJ
            reactive_JJ oxygen_NN species_NNS that_WDT can_MD attack_VB mtDNA_NN ,_, membrane_NN
            lipids_NNS ,_, carbohydrates_NNS and_CC proteins_NNS ._. This_DT can_MD damage_VB the_DT
            entire_JJ oxidative_JJ phosphorylation_NN system_NN ,_, especially_RB the_DT
            highly_RB vulnerable_JJ iron-sulfur_JJ centers_NNS ._. The_DT shortage_NN of_IN
            frataxin_NN does_VBZ not_RB result_VB from_IN formation_NN of_IN mutant_JJ
            proteins_NNS ,_, but_CC rather_RB from_IN expansion_NN of_IN a_DT GAA_NNP repeat_NN in_IN
            the_DT first_JJ intron_NN of_IN the_DT frataxin_NN gene_NN ._. This_DT expanded_VBN
            repeat_NN is_VBZ believed_VBN to_TO form_VB localized_JJ RNA_NNP secondary_JJ
            structures_NNS that_WDT interfere_VBP with_IN transcription_NN [_NN 31_CD ,_, 32_CD ]_NN ._.
            Yfh_NNP 1_CD p_NN (_( YDL_NNP 120_CD W_NNP )_) ,_, the_DT frataxin_NN homolog_NN in_IN yeast_NN ,_,
            interacts_NNS with_IN the_DT yeast_NN mitochondrial_NN intermediate_JJ
            peptidase_NN (_( Oct_NNP 1_CD ,_, YKL_NNP 134_CD C_NNP )_) to_TO lower_JJR matrix_NN iron_NN
            concentration_NN ,_, directly_RB and_CC by_IN competition_NN [_NN 33_CD ]_NN ._.
            Normal_NNP mitochondrial_NN iron_NN homeostasis_NNS minimally_RB
            depends_VBZ on_IN wild-type_JJ frataxin_NN to_TO control_VB efflux_NN ._. Both_DT
            proteolytic_JJ cleavage_NN (_( via_IN MPP_NNP and_CC /_NN or_CC IMP_NNP complexes_NNS )_) and_CC
            chaperonin_NN help_NN (_( mt-_NN HSP_NNP 70_CD /_NN Ssc_NNP 2_CD p_NN )_) in_IN membrane_NN
            trafficking_NN and_CC /_NN or_CC folding_VBG are_VBP needed_VBN for_IN the_DT mature_VBP
            frataxin_NN protein_NN to_TO arrive_VB at_IN its_PRP$ destination_NN in_IN the_DT
            matrix_NN in_IN its_PRP$ proper_JJ conformation_NN ._. Iron_NNP efflux_NN also_RB
            depends_VBZ upon_IN the_DT iron-sulfur_JJ cluster_NN transporter_NN Atm_NNP 1_CD p_NN
            (_( YMR_NNP 301_CD C_NNP )_) ._. A_DT missense_NN mutation_NN in_IN Abcb_NNP 7_CD (_( or_CC hABC_NN 7_CD the_DT
            human_JJ homolog_NN of_IN Atm_NNP 1_CD p_NN )_) ,_, Ile_NNP 400_CD →_NN Met_NNP ,_, has_VBZ been_VBN
            implicated_VBN in_IN X-_NNP linked_VBD sideroblastic_JJ anemia_NN and_CC ataxia_NN
            [_NN 34_CD ]_NN ,_, a_DT disorder_NN closely_RB related_VBD to_TO Friedreich_NNP 's_POS
            ataxia_NN ._. Figure_NN 10_CD summarizes_NNS the_DT sequence_NN and_CC
            phylogenetic_JJ context_NN for_IN this_DT pathogenic_JJ change_NN ._. No_DT
            experimental_JJ structural_JJ data_NNS are_VBP available_JJ ,_, but_CC
            discrete_JJ state-space_JJ models_NNS [_NN 35_CD ,_, 36_CD ]_NN (_( H_NNP ._. He_PRP ,_, G_NNP ._.
            McAllister_NNP and_CC T_NN ._. F_NN ._. Smith_NNP ,_, manuscript_NN in_IN preparation_NN )_)
            for_IN membrane_NN proteins_NNS clearly_RB indicate_VBP that_IN the_DT
            mutation_NN falls_VBZ in_IN an_DT extracellular_NN tight_JJ turn_NN between_IN
            transmembrane_NN helices_NNS five_CD and_CC six_CD ._.
            A_DT pair_NN of_IN cation_NN transporters_NNS ,_, Mmt_NNP 1_CD (_( YMR_NNP 177_CD W_NNP )_) and_CC
            Mmt_NNP 2_CD (_( YPL_NNP 224_CD C_NNP )_) in_IN yeast_NN ,_, controls_NNS iron_NN influx_NN into_IN the_DT
            mitochondria_NN ._. This_DT other_JJ half_NN of_IN iron_NN homeostasis_NNS could_MD
            also_RB easily_RB have_VB a_DT role_NN in_IN Friedreich_NNP 's_POS ataxia_NN and_CC
            X-_NNP linked_VBD sideroblastic_JJ anemia_NN ._.
          
          
            Hereditary_NNP spastic_JJ paraplegia_NN
            Hereditary_NNP spastic_JJ paraplegia_NN (_( HSP_NNP )_) ,_, a_DT class_NN II_NNP
            assembly_NN disorder_NN ,_, is_VBZ characterized_VBN by_IN progressive_JJ ,_,
            usually_RB severe_JJ ,_, lower_JJR extremity_NN spasticity_NN due_JJ to_TO
            degeneration_NN of_IN the_DT long_JJ axons_NNS of_IN the_DT central_JJ nervous_JJ
            system_NN (_( while_IN the_DT cell_NN bodies_NNS remain_VBP intact_JJ )_) ._.
            Inheritance_NNP can_MD be_VB autosomal_NN dominant_JJ ,_, autosomal_NN
            recessive_JJ or_CC X-_NNP linked_VBD ._. Some_DT cases_NNS of_IN HSP_NNP result_NN from_IN
            mutations_NNS in_IN the_DT gene_NN for_IN paraplegin_NN ,_, a_DT nuclear-encoded_JJ
            mitochondrial_NN metalloprotease_NN ,_, including_VBG :_: a_DT 2_CD bp_NN
            deletion_NN at_IN position_NN 784_CD ,_, which_WDT causes_VBZ a_DT frameshift_NN
            that_WDT eliminates_VBZ 60_CD %_NN of_IN the_DT protein_NN ;_: and_CC an_DT adenine_NN
            insertion_NN at_IN position_NN 2_CD ,_, 228_CD of_IN the_DT paraplegin_NN cDNA_NN ,_,
            which_WDT creates_VBZ a_DT frameshift_NN resulting_VBG in_IN truncation_NN of_IN
            the_DT last_JJ 57_CD residues_NNS of_IN this_DT 795_CD -_: residue_NN protein_NN [_NN 37_CD ]_NN ._.
            As_IN shown_VBN in_IN Figure_NN 11_CD ,_, there_EX are_VBP very_RB few_JJ well_RB
            conserved_JJ positions_NNS in_IN the_DT deleted_VBN 57_CD -_: residue_NN tail_NN ,_,
            implying_VBG that_IN this_DT may_MD be_VB a_DT comparatively_RB disordered_JJ
            part_NN of_IN the_DT protein_NN ._. No_DT missense_NN mutations_NNS have_VBP been_VBN
            found_VBN in_IN human_JJ paraplegin_NN to_TO date_NN ._. This_DT protein_NN
            resembles_VBZ three_CD yeast_NN proteins_NNS which_WDT function_VBP as_IN
            chaperonins_NNS and_CC /_NN or_CC proteases_NNS :_: Afg_NNP 3_CD p_NN (_( YER_NNP 017_CD C_NNP )_) ,_, Rca_NNP 1_CD p_NN
            (_( YMRo_NNP 89_CD C_NNP )_) and_CC Yme_NNP 1_CD p_NN (_( YPR_NNP 024_CD W_NNP )_) ._. They_PRP participate_VBP in_IN
            recycling_VBG the_DT components_NNS of_IN complex_JJ V_NNP (_( ATP_NNP synthase_NN )_) as_RB
            well_RB as_IN in_IN its_PRP$ assembly_NN ._. The_DT products_NNS of_IN YER_NNP 017_CD C_NNP and_CC
            YMR_NNP 089_CD C_NNP make_VB up_RP the_DT mitochondrial_NN adenosine_NN
            triphosphatase_NN (_( m-_NN AAA_NNP )_) protease_NN complex_NN ,_, which_WDT is_VBZ
            embedded_VBN in_IN the_DT inner_JJ mitochondrial_NN membrane_NN facing_VBG the_DT
            matrix_NN ._. YPR_NNP 024_CD W_NNP encodes_NNS the_DT i-_NN AAA_NNP protease_NN complex_NN ,_,
            which_WDT faces_VBZ the_DT intermembrane_NN space_NN ._.
            The_DT yeast_NN m-_NN AAA_NNP protease_NN complex_NN is_VBZ itself_PRP regulated_VBN
            by_IN two_CD prohibitin_NN proteins_NNS ,_, Phb_NNP 1_CD (_( YGR_NNP 132_CD C_NNP )_) and_CC Phb_NNP 2_CD
            (_( YGR_NNP 231_CD C_NNP )_) [_NN 38_CD ]_NN ._. Paraplegin_NNP homologs_NNS ,_, analogous_JJ to_TO the_DT
            yeast_NN paralogs_NNS Afg_NNP 3_CD p_NN ,_, Rca_NNP 1_CD p_NN and_CC Yme_NNP 1_CD p_NN ,_, must_MD almost_RB
            certainly_RB exist_VB ,_, and_CC human_JJ prohibitins_NNS may_MD be_VB expected_VBN
            as_RB well_RB ._. Point_NNP mutations_NNS in_IN conserved_JJ regions_NNS of_IN these_DT
            proteins_NNS can_MD be_VB expected_VBN to_TO cause_VB missense_NN mutations_NNS
            and_CC translational_NN truncations_NNS that_WDT will_MD also_RB lead_VB to_TO
            hereditary_JJ spastic_JJ paraplegia_NN ._.
          
        
      
      
        Discussion_NNP
        The_DT process_NN of_IN understanding_NN genetic_JJ disease_NN typically_RB
        proceeds_VBZ through_IN three_CD stages_NNS :_: first_JJ ,_, recognition_NN of_IN the_DT
        disease_NN state_NN or_CC syndrome_NN including_VBG its_PRP$ hereditary_JJ
        character_NN ;_: second_JJ ,_, discovery_NN and_CC mapping_NN of_IN the_DT related_VBN
        mutation_NN (_( s_VBZ )_) ;_: and_CC third_JJ ,_, elucidation_NN of_IN the_DT
        biochemical_JJ /_NN biophysical_JJ mechanism_NN leading_VBG to_TO the_DT disease_NN
        phenotype_NN ._. Sickle-cell_NNP anemia_NN provides_VBZ the_DT classic_JJ example_NN ._.
        In_IN the_DT case_NN of_IN mitochondrial_NN diseases_NNS there_RB are_VBP more_JJR than_IN
        100_CD described_VBD conditions_NNS (_( OMIM_NNP [_NN 39_CD ]_NN ,_, MITOP_NNP [_NN 40_CD ]_NN ,_, and_CC
        WUSTL_NNP [_NN 5_CD ]_NN websites_NNS )_) and_CC a_DT comparable_JJ (_( and_CC growing_VBG !_. )_) number_NN
        of_IN mutations_NNS [_NN 8_CD ]_NN ._. As_IN already_RB described_VBD for_IN LHON_NNP ,_, Leigh_NNP
        syndrome_NN and_CC HSP_NNP ,_, the_DT causative_JJ mutations_NNS are_VBP not_RB
        necessarily_RB confined_VBN to_TO a_DT single_JJ protein-coding_JJ gene_NN ,_, or_CC
        even_RB to_TO the_DT nuclear_JJ versus_CC the_DT mitochondrial_NN genome_NN ._. Put_VB
        differently_RB ,_, there_EX is_VBZ no_DT one-to-one_JJ mapping_NN between_IN
        mutations_NNS (_( or_CC even_RB whole_JJ genes_NNS )_) and_CC a_DT particular_RB defined_VBN
        disease_NN entity_NN ._. Thus_RB ,_, each_DT disease_NN spectrum_NN may_MD correspond_VB
        to_TO several_JJ sets_NNS of_IN mutations_NNS ,_, each_DT set_VBN affecting_VBG one_CD
        protein_NN or_CC protein_NN subunit_NN ._. Obviously_RB ,_, mutations_NNS in_IN
        mt-t_JJ RNA_NNP ,_, mt-r_JJ RNA_NNP and_CC proteins_NNS that_WDT affect_VBP mitochondrial_NN
        gene_NN expression_NN will_MD also_RB potentially_RB have_VB pleiotropic_JJ
        effects_NNS ._.
        The_DT results_NNS presented_VBN here_RB address_VB the_DT third_JJ stage_NN of_IN
        understanding_NN genetic_JJ disease_NN ,_, namely_RB the_DT characterization_NN
        of_IN the_DT disease_NN phenotype_NN at_IN the_DT molecular_JJ level_NN with_IN a_DT view_NN
        to_TO explaining_VBG its_PRP$ biochemical_JJ mechanism_NN ._. In_IN principle_NN ,_, the_DT
        approach_NN can_MD be_VB applied_VBN to_TO any_DT mutated_VBN protein-coding_JJ gene_NN ._.
        When_WRB structural_JJ information_NN is_VBZ available_JJ ,_, the_DT exact_JJ
        mechanism_NN of_IN disease_NN causation_NN may_MD be_VB ascertainable_JJ at_IN the_DT
        molecular_JJ level_NN -_: and_CC testable_JJ by_IN means_NNS of_IN carefully_RB
        targeted_VBN experiments_NNS ._. A_DT further_JJ extension_NN of_IN this_DT
        basic-knowledge_JJ approach_NN lies_VBZ in_IN the_DT direction_NN of_IN molecular_JJ
        evolution_NN ._. As_IN we_PRP will_MD show_VB elsewhere_RB (_( T_NN ._. P_NN ._. ,_, T_NN ._. F_NN ._. S_NNP ._. and_CC
        S_NNP ._. C_NNP ._. M_NNP ._. ,_, unpublished_JJ observations_NNS )_) ,_, the_DT extended_VBN sets_NNS of_IN
        homologs_NNS assembled_VBD using_VBG prior-based_JJ profiles_NNS provide_VBP a_DT
        rich_JJ source_NN of_IN phylogenetic_JJ information_NN ._. Not_RB only_RB should_MD it_PRP
        be_VB possible_JJ to_TO sketch_NN out_RP the_DT history_NN of_IN the_DT development_NN of_IN
        different_JJ biochemical_JJ machineries_NNS ,_, it_PRP should_MD also_RB be_VB
        possible_JJ to_TO establish_VB which_WDT parts_NNS of_IN the_DT proteins_NNS are_VBP most_RBS
        critical_JJ to_TO function_VB on_IN the_DT basis_NN of_IN amino-acid_JJ sequence_NN
        conservation_NN correlated_JJ with_IN the_DT structural_JJ contexts_NNS ._.
        Knowledge_NNP gained_VBN by_IN the_DT approach_NN described_VBD here_RB has_VBZ
        obvious_JJ application_NN to_TO both_DT the_DT diagnosis_NN and_CC therapy_NN of_IN
        mitochondrial_NN diseases_NNS ._. Once_RB a_DT mutation_NN has_VBZ been_VBN
        characterized_VBN ,_, the_DT exact_JJ nature_NN of_IN the_DT associated_VBN illness_NN
        is_VBZ known_VBN with_IN precision_NN ._. This_DT has_VBZ a_DT bearing_NN upon_IN choice_NN of_IN
        therapy_NN and_CC allows_VBZ a_DT much_RB more_RBR exact_JJ prognosis_NN than_IN a_DT
        characterization_NN simply_RB as_RB ,_, say_VB ,_, Leigh_NNP syndrome_NN ._. In_IN
        addition_NN ,_, the_DT information_NN from_IN sequence_NN alignments_NNS has_VBZ
        predictive_JJ power_NN :_: mutations_NNS not_RB yet_RB recorded_VBN in_IN the_DT
        literature_NN might_MD turn_VB up_RB at_IN key_JJ positions_NNS in_IN some_DT of_IN the_DT
        proteins_NNS known_VBN to_TO be_VB affected_VBN in_IN mitochondrial_NN diseases_NNS ._.
        Individuals_NNS carrying_VBG such_JJ changes_NNS might_MD be_VB alerted_VBD to_TO the_DT
        possible_JJ harmful_JJ consequences_NNS and_CC take_VB whatever_WDT
        precautionary_JJ measures_NNS seem_VBP appropriate_JJ ._. (_( Note_VB that_IN
        substitutions_NNS in_IN the_DT human_JJ sequence_NN that_WDT match_VBP amino-acid_JJ
        residues_NNS found_VBD at_IN the_DT corresponding_JJ locations_NNS in_IN
        taxonomically_RB distant_JJ sequences_NNS are_VBP less_RBR likely_JJ to_TO prove_VB
        harmful_JJ than_IN completely_RB novel_NN substitutions_NNS ._. )_) This_DT
        application_NN of_IN informatics_NNS data_NNS will_MD certainly_RB grow_VB in_IN
        importance_NN as_IN acquisition_NN of_IN additional_JJ single-nucleotide_JJ
        polymorphism_NN (_( SNP_NNP )_) data_NNS becomes_VBZ increasingly_RB common_JJ and_CC new_JJ
        paralogs_NNS and_CC orthologs_NNS are_VBP added_VBN to_TO the_DT sequence_NN database_NN ._.
        Finally_RB ,_, depending_VBG on_IN the_DT nature_NN of_IN the_DT affected_VBN protein_NN
        and_CC the_DT frequency_NN of_IN occurrence_NN of_IN diseased_JJ individuals_NNS ,_, it_PRP
        may_MD be_VB possible_JJ to_TO use_VB the_DT data_NNS for_IN attempts_NNS at_IN rational_JJ
        drug_NN design_NN or_CC gene_NN therapy_NN ._.
        The_DT work_NN reported_VBD here_RB represents_VBZ a_DT preliminary_JJ overview_NN
        of_IN the_DT field_NN ._. Eventually_RB ,_, an_DT exhaustive_JJ survey_NN should_MD be_VB
        completed_VBN ,_, continuously_RB updated_VBN and_CC made_VBN publicly_RB
        available_JJ ._. That_DT will_MD require_VB precise_JJ characterization_NN of_IN
        many_JJ more_JJR mutations_NNS as_RB well_RB as_IN expansion_NN of_IN the_DT database_NN of_IN
        mitochondrial_NN protein_NN profiles_NNS beyond_IN what_WP we_PRP have_VBP
        constructed_VBN using_VBG yeast_NN as_IN a_DT model_NN ._. Such_JJ efforts_NNS are_VBP
        underway_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Yeast_NN mitochondrial_NN protein_NN database_NN (_( YMPD_NNP )_)
          We_PRP created_VBD a_DT database_NN of_IN >_NN 430_CD yeast_NN mitochondrial_NN
          proteins_NNS using_VBG biochemical_JJ keyword_NN searches_NNS for_IN known_VBN
          mitchondrial_NN processes_VBZ from_IN the_DT 
          Saccharomyces_NNP Genome_NNP Database_NNP [_NN
          41_CD ]_NN ,_, the_DT Munich_NNP Information_NNP Center_NNP for_IN Protein_NNP Sequences_NNP
          [_NN 42_CD ]_NN ,_, the_DT Yeast_NN Proteome_NNP Database_NNP [_NN 43_CD ]_NN ,_, and_CC MitBASE_NNP [_NN
          44_CD ]_NN ,_, and_CC by_IN monitoring_VBG the_DT current_JJ literature_NN ._. Each_DT
          member_NN of_IN this_DT set_JJ of_IN proteins_NNS is_VBZ characterized_VBN by_IN at_IN
          least_JJS one_CD prior-based_JJ profile_NN [_NN 1_CD ]_NN that_WDT represents_VBZ the_DT
          most_RBS conserved_JJ region_NN (_( s_VBZ )_) ._.
          As_IN 
          S_NNP ._. cerevisiae_NN does_VBZ not_RB use_VB a_DT
          canonical_JJ mitochondrial_NN complex_JJ I_PRP we_PRP have_VBP substituted_VBN the_DT
          NADH_NNP dehydrogenase_NN protein_NN subunits_NNS from_IN 
          R_NN ._. americana_NN to_TO initialize_NN these_DT
          profiles_NNS ._.
        
        
          Developing_VBG prior-based_JJ profiles_NNS
          Prior-based_NNP profiles_NNS [_NN 1_CD ]_NN ,_, the_DT principal_JJ tools_NNS used_VBN in_IN
          this_DT work_NN ,_, represent_VB evolutionarily_RB conserved_JJ ,_,
          sequence-based_JJ ,_, functional_JJ domains_NNS ._. Once_RB created_VBN ,_, each_DT
          profile_NN can_MD be_VB used_VBN to_TO search_VB all_DT available_JJ databases_NNS in_IN
          an_DT attempt_NN to_TO locate_VB all_DT homologous_RB sequence_NN matches_VBZ -_:
          which_WDT in_IN ideal_JJ cases_NNS correspond_VB to_TO single_VB protein_NN
          domains_NNS ._. This_DT expanded_VBN set_NN of_IN homologous_RB sequences_NNS is_VBZ
          then_RB multiply-aligned_JJ using_VBG the_DT profile_NN as_IN a_DT template_NN ._.
          The_DT set_NN of_IN multiply-aligned_JJ sequences_NNS defines_VBZ
          sequence-domain_JJ boundaries_NNS ,_, allows_VBZ putative_JJ functional_JJ
          assignments_NNS for_IN previously_RB unidentified_JJ proteins_NNS and_CC
          highlights_VBZ key_JJ conserved_JJ residues_NNS of_IN members_NNS of_IN a_DT
          homologous_RB set_NN of_IN proteins_NNS ._. As_IN new_JJ sequences_NNS (_( and_CC
          sequenced_JJ genomes_NNS )_) become_VB available_JJ ,_, our_PRP$ set_NN of_IN profiles_NNS
          can_MD identify_VB the_DT additional_JJ homologs_NNS with_IN high_JJ
          sensitivity_NN and_CC specificity_NN [_NN 1_CD ]_NN ._.
        
        
          The_DT profile-defining_JJ set_VBN
          A_DT defining_VBG set_VBN with_IN a_DT wide_JJ taxonomic_JJ spread_NN should_MD be_VB
          optimal_NN for_IN locating_VBG distant_JJ homologs_NNS from_IN as_IN many_JJ
          species_NNS as_IN possible_JJ ._. Ideal_NN profiles_NNS have_VBP a_DT defining_VBG set_VBN
          composed_VBN of_IN one_CD protein_NN each_DT from_IN a_DT eukaryote_NN ,_, an_DT
          archaeon_NN ,_, a_DT Gram-positive_NNP bacterium_NN and_CC a_DT Gram-negative_NNP
          bacterium_NN ,_, and_CC one_CD yeast_NN mitochondrial_NN protein_NN ._. To_TO create_VB
          the_DT defining_VBG set_VBN for_IN each_DT profile_NN ,_, we_PRP established_VBD a_DT
          superset_NN of_IN potential_JJ family_NN members_NNS using_VBG BLAST_NN searches_NNS
          [_NN 45_CD ]_NN against_IN our_PRP$ Biomolecular_NNP Engineering_NNP Research_NNP
          Center_NNP (_( BMERC_NNP )_) all-genomes_JJ database_NN and_CC Swiss-_NNP Prot_NNP [_NN 46_CD ]_NN ._.
          Each_DT identified_VBN yeast_NN mitochondrial_NN protein_NN serves_VBZ as_IN a_NNP
          '_POS seed_NN '_'' (_( initializing_VBG protein_NN )_) for_IN a_DT BLAST_NN search_NN ._. The_DT
          cutoff_NN scores_NNS are_VBP set_VBN at_IN an_DT expectation_NN value_NN of_IN E_NNP =_SYM 10_CD
          -_: 6_CD using_VBG the_DT standard_JJ SEG_NNP and_CC XNU_NNP filters_NNS for_IN
          low-complexity_JJ regions_NNS [_NN 47_CD ]_NN ._. From_IN these_DT BLAST_NN hits_NNS we_PRP
          selected_VBD the_DT initial_JJ defining_VBG set_NN of_IN maximum_NN taxonomic_JJ
          spread_NN ._. In_IN some_DT cases_NNS ,_, BLAST_NN fails_VBZ to_TO locate_VB sequence_NN
          homologs_NNS that_WDT have_VBP diverged_JJ greatly_RB from_IN the_DT seed_NN
          mitochondrial_NN protein_NN ._. We_PRP then_RB used_VBD an_DT iterative_JJ
          procedure_NN to_TO generate_VB a_DT profile_NN using_VBG local_JJ dynamic_JJ
          programming_NN ,_, to_TO maximize_VB the_DT information_NN content_NN ._. For_IN
          such_JJ cases_NNS ,_, the_DT initial_JJ profile_NN is_VBZ run_VB against_IN the_DT
          all-genomes_JJ database_NN by_IN exhaustive_JJ local_JJ dynamic_JJ
          programming_NN ._. Then_RB the_DT next_JJ highest_JJS scoring_VBG member_NN from_IN a_DT
          different_JJ kingdom_NN is_VBZ added_VBN to_TO the_DT defining_VBG set_VBN ._. We_PRP
          iterated_JJ this_DT process_NN until_IN the_DT ideal_JJ taxonomic_JJ spread_NN
          was_VBD achieved_VBN or_CC the_DT information_NN content_NN of_IN the_DT profile_NN
          dropped_VBD below_IN ten_CD amino-acid_JJ equivalencies_NNS [_NN 48_CD ]_NN ._.
        
        
          Expanding_NNP the_DT set_NN of_IN profile_NN homologs_NNS
          Once_RB a_DT profile_NN is_VBZ built_VBN we_PRP attempt_VBP to_TO find_VB all_DT
          sequences_NNS sharing_VBG this_DT sequence_NN domain_NN ._. This_DT is_VBZ done_VBN by_IN
          heuristic_JJ and_CC /_NN or_CC exhaustive_JJ approaches_NNS ._. In_IN the_DT heuristic_JJ
          approach_NN the_DT profile_NN searches_VBZ BMERC_NNP 's_POS all-genomes_JJ and_CC
          Swiss-_NNP Prot_NNP by_IN filtering_VBG the_DT larger_JJR databases_NNS using_VBG BLAST_NN
          with_IN an_DT expectation_NN value_NN cutoff_NN of_IN E_NNP =_SYM 10_CD -_: 2_CD ,_, followed_VBN
          by_IN a_DT short-in-long_JJ profile_NN search_NN ._. In_IN the_DT exhaustive_JJ
          approach_NN ,_, the_DT profile_NN searches_VBZ the_DT all-genomes_JJ database_NN
          or_CC the_DT current_JJ version_NN of_IN Swiss-_NNP Prot_NNP using_VBG short-in-long_JJ
          dynamic_JJ programming_NN ._.
        
        
          Multiple_NNP alignment_NN sets_NNS
          Each_DT profile_NN induces_VBZ a_DT multiple_JJ alignment_NN for_IN any_DT set_NN
          of_IN proteins_NNS that_WDT contain_VBP it_PRP ._. The_DT profiles_NNS only_RB align_VBP
          those_DT subregions_NNS of_IN a_DT protein_NN that_IN they_PRP match_VBP ._. These_DT
          regions_NNS incorporate_VB the_DT most_RBS conserved_JJ amino-acid_JJ
          positions_NNS among_IN the_DT sequences_NNS that_WDT make_VBP up_RP the_DT profile_NN 's_POS
          defining_VBG set_VBN ._. We_PRP have_VBP chosen_VBN defining_VBG sets_NNS that_WDT contain_VBP
          the_DT shortest_JJS informative_JJ protein_NN sequence_NN in_IN order_NN to_TO
          maximize_VB the_DT chance_NN of_IN producing_VBG single-domain_JJ profile_NN
          objects_NNS ._. A_DT longer_JJR sequence_NN in_IN the_DT defining_VBG set_VBN might_MD make_VB
          a_DT slightly_RB higher-scoring_JJ profile_NN by_IN the_DT addition_NN of_IN a_DT
          few_JJ carboxy-_NN or_CC amino-terminal_JJ residues_NNS ,_, but_CC only_RB at_IN the_DT
          risk_NN of_IN missing_VBG slightly_RB shorter_JJR members_NNS of_IN the_DT set_VBN when_WRB
          the_DT profile_NN is_VBZ used_VBN to_TO search_VB the_DT databases_NNS ._.
        
        
          Homologous_NNP structures_NNS from_IN the_DT Protein_NNP Data_NNP
          Bank_NNP
          We_PRP routinely_RB search_VBP the_DT RCSB_NNP Protein_NNP Data_NNP Bank_NNP [_NN 49_CD ]_NN ,_,
          for_IN potential_JJ structural_JJ homologs_NNS ._. Profile_NNP matches_VBZ with_IN
          Z-_NNP scores_NNS above_IN 10_CD are_VBP retained_VBN and_CC used_VBN to_TO align_VBP the_DT
          profile-matched_JJ region_NN to_TO a_DT structural_JJ domain_NN ._. These_DT
          profile-induced_JJ structural_JJ alignments_NNS can_MD be_VB visualized_JJ
          in_IN Rasmol_NNP [_NN 50_CD ]_NN ,_, and_CC images_NNS built_VBD using_VBG Molscript_NNP [_NN 51_CD ]_NN
          and_CC Rasters_NNP 3_CD D_NNP [_NN 52_CD ]_NN ._.
        
      
      
        Additional_JJ data_NNS files_NNS
        The_DT following_VBG additional_JJ data_NNS files_NNS are_VBP available_JJ with_IN
        this_DT paper_NN online_NN :_: complete_JJ alignments_NNS for_IN the_DT
        profile-covered_JJ regions_NNS of_IN the_DT sequences_NNS shown_VBN in_IN Figure_NN 1_CD (_(
        additonal_NN data_NNS file_VBP 1_LS )_) ,_, Figure_NN 2_CD (_( additonal_NN data_NNS file_VBP 2_LS )_) ,_,
        Figure_NN 3_CD (_( additonal_NN data_NNS file_VBP 3_LS )_) ,_, Figure_NN 4_CD (_( additonal_NN data_NNS
        file_VBP 4_LS )_) ,_, Figure_NN 5_CD (_( additonal_NN data_NNS file_VBP 5_LS )_) ,_, Figure_NN 6_CD (_(
        additonal_NN data_NNS file_VBP 6_CD )_) ,_, Figure_NN 7_CD (_( additonal_NN data_NNS file_VBP 7_CD )_) ,_,
        Figure_NN 8_CD (_( additonal_NN data_NNS file_VBP 8_CD )_) ,_, Figure_NN 9_CD (_( additonal_NN data_NNS
        file_VBP 9_CD )_) ,_, Figure_NN 10_CD (_( additonal_NN data_NNS file_VBP 10_CD )_) and_CC Figure_NN 11_CD (_(
        additonal_NN data_NNS file_VBP 11_CD )_) ._.
        Additional_JJ data_NNS file_VBP 1_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 1_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 2_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 2_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 3_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 3_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 4_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 4_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 5_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 5_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 6_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 6_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 7_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 7_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 8_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 8_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 9_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 9_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 10_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 10_CD
        Click_NNP here_RB for_IN file_NN
        Additional_JJ data_NNS file_VBP 11_CD
        Alignments_NNP for_IN the_DT regions_NNS shown_VBN in_IN figure_NN 11_CD
        Click_NNP here_RB for_IN file_NN
      
    
  
